<DOC>
	<DOCNO>NCT00470678</DOCNO>
	<brief_summary>This study evaluate efficacy safety monthly ranibizumab 0.5 mg intravitreal injection Asian patient subfoveal choroidal neovascularization secondary age-related macular degeneration .</brief_summary>
	<brief_title>EXTEND III - Efficacy Safety Ranibizumab Patients With Subfoveal Choroidal Neovascularization ( CNV ) Secondary Age-related Macular Degeneration ( AMD )</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Male female Asian patient 50 year age great . Patients primary recurrent subfoveal CNV secondary AMD , include predominantly classic , minimally classic active occult lesion classic component . Patients BCVA score 73 24 letter ( approximately 20/40 20/320 Snellen equivalent ) , inclusively , study eye . Total area CNV ( include classic occult component ) encompass within lesion must &gt; = 50 % total lesion area Total lesion area must &lt; = 12 disc area Patients fellow eye Snellen equivalent 20/200 Presence angioid streak , presume ocular histoplasmosis syndrome , myopia ( exceed 8 diopter ) , CNV secondary cause AMD study eye Subfoveal fibrosis atrophy study eye Total area CNV ( include classic occult component ) encompass within lesion must &gt; = 50 % total lesion area Total lesion area must &lt; = 12 disc area Vitreous hemorrhage , retinal tear history rhegmatogenous retinal detachment macular hole ( Stage 3 4 ) study eye . Active , history , ocular inflammation infection study eye within last 30 day prior screen . Uncontrolled glaucoma study eye Treatment study eye verteporfin , externalbeam radiation therapy , subfoveal focal laser photocoagulation , vitrectomy , submacular surgery , transpupillary thermotherapy within 30 day prior screen Previous treatment antiangiogenic drug ( pegaptanib , ranibizumab , bevacizumab , anecortave acetate , corticosteroid , protein kinase C inhibitor , squalamine , siRNA , VEGFTrap etc . ) neovascular AMD study eye . Treatment fellow eye permit administered &gt; 30 day screen . History intraocular surgery study eye include par plana vitrectomy , except uncomplicated cataract surgery 60 day prior screen History YAG laser posterior capsulotomy study eye within 30 day prior screen</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Age-related</keyword>
	<keyword>macular</keyword>
	<keyword>degeneration</keyword>
	<keyword>AMD</keyword>
	<keyword>Ranibizumab</keyword>
	<keyword>Anti-VEGF</keyword>
	<keyword>choroidal</keyword>
	<keyword>neovascularization</keyword>
	<keyword>CNV</keyword>
	<keyword>Asian patient</keyword>
	<keyword>Korea</keyword>
	<keyword>Taiwan</keyword>
	<keyword>associate</keyword>
</DOC>